Madrigal Pharmaceuticals (MDGL) Peer Comparison
$467.54
$20.45
(4.57%)
As on 20-Oct-2026 16:25EDT
Market cap
$10,391 Mln
Revenue (TTM)
$1,284 Mln
P/E Ratio
--
P/B Ratio
22.6
Div. Yield
0 %
Edit
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
10,391 | 17,263 | 14,822 | 15,419 | 13,829 |
Revenue ($ Mln) |
1,284 | 2,782 | 1,054 | 2,436 | 1,664 |
Net Profit ($ Mln) |
-325.10 | 491.50 | 755.85 | 860.62 | 413.60 |
Net Margin (%) |
-25.32 | 17.67 | 71.69 | 35.33 | 24.86 |
RoE (%) |
-57.72 | 110.09 | -- | 42.98 | 430.03 |
Price to Earnings |
-- | 36.32 | 17.26 | 19.63 | 35.63 |
Price-To-Book |
22.63 | 39.70 | 8.91 | 7.82 | 88.91 |
Income Statement ($ Mln)
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,283.94 | 2,782.29 | 1,054.37 | 2,435.92 | 1,663.74 |
|
Cost of Revenue
|
109.42 | 1,982.07 | 103.47 | 85.67 | 292.42 |
|
Gross Profit
|
902.26 | 760.62 | 588.53 | 2,236.43 | 1,167.84 |
|
Operating Expenses
|
1,497.13 | 216.81 | 841.45 | 1,378.74 | 440.53 |
|
Operating Profit (EBIT)
|
-322.62 | 583.40 | 109.45 | 971.51 | 930.79 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-325.10 | 598.92 | 101.11 | 1,035.47 | 583.34 |
|
Provision for Tax
|
0.00 | 107.42 | -654.74 | 174.84 | 169.74 |
|
Profit after Tax (Net Income)
|
-325.10 | 491.50 | 755.85 | 860.62 | 413.60 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
523.72 | 433.86 | 1,435.90 | 1,843.76 | 143.54 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
346.72 | 187.89 | 384.48 | 288.55 | 2,089.43 |
|
Current Liabilities
|
374.20 | 1,435.43 | 464.70 | 361.93 | 344.44 |
|
Total Liabilities
|
1,259.59 | 1,975.47 | 1,302.02 | 2,844.42 | 2,525.32 |
Assets ($ Mln)
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
45.47 | 1,006.90 | 895.24 | 1,243.41 | 1,644.38 |
|
Current Assets
|
1,199.18 | 1,050.29 | 1,389.84 | 1,250.82 | 933.02 |
|
Total Assets
|
1,259.59 | 1,975.47 | 1,302.02 | 2,844.42 | 2,525.32 |
|
Total Debt*
|
347.75 | 144.11 | 449.89 | 165.93 | 2,146.65 |
|
Net Current Assets
|
824.98 | -385.14 | 925.52 | 888.90 | 588.59 |
Cashflow ($ Mln)
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-189.55 | 713.22 | 51.77 | 884.27 | 651.56 |
|
Cash Flow from Investing Activities
|
32.32 | -31.14 | -8.15 | 350.44 | -545.81 |
|
Cash from Financing Activities
|
255.98 | -860.39 | 34.89 | -969.59 | -85.17 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-31.49 | 57.43 | -30.01 | 32.82 | 15.61 |
|
ROE (%)
|
-57.72 | 110.09 | 163.18 | 42.98 | 430.03 |
|
ROA (%)
|
-22.97 | 15.64 | 31.68 | 29.32 | 16.19 |
|
EBIT Margin (%)
|
-22.87 | 21.13 | 5.73 | 41.82 | 36.28 |
|
Net Margin (%)
|
-25.32 | 17.67 | 71.69 | 35.33 | 24.86 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
149.04 | 24.67 | 114.85 | 9.23 | 41.15 |
|
EBIT Growth (%)
|
-9.48 | 18.70 | 136.39 | 29.37 | -14.99 |
|
Net Profit Growth (%)
|
-15.32 | 17.50 | 378.76 | 42.89 | -25.78 |
|
EPS Growth (%)
|
-0.64 | 26.84 | 353.27 | 50.42 | -23.48 |
|
Book Value Growth (%)
|
-42.66 | 164.02 | 816.12 | -0.70 | -55.81 |
Valuation Ratios
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-45.32 | 36.06 | -59.76 | 15.79 | 24.99 |
|
Price / Book Value
|
21.68 | 35.44 | -80.42 | 5.72 | 162.23 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-47.02 | 27.88 | -121.54 | 12.44 | 17.31 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.65 | 0.00 | 0.27 | 0.00 | 13.50 |
|
Short term debt to equity ratio
|
0.00 | 0.06 | 0.05 | 0.00 | 1.46 |
|
Current Ratio
|
3.20 | 0.73 | 2.99 | 3.46 | 2.71 |
|
Quick Ratio
|
2.94 | 0.73 | 2.32 | 3.38 | 2.31 |
|
Interest Coverage
|
-9.32 | -- | 1.62 | -- | 29.73 |
Operating Efficiency Ratios
| Madrigal Pharmaceuticals (MDGL) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Halozyme Therapeutics (HALO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
14.98 | 15.88 | 21.25 | 13.74 | 27.40 |
|
Asset Turnover
|
0.91 | 0.89 | 0.44 | 0.83 | 0.65 |
|
Receivable days
|
35.88 | 50.42 | 85.52 | 43.48 | 98.04 |
|
Inventory Days
|
354.23 | -- | 1,056.70 | 96.17 | 254.12 |
|
Payable days
|
300.79 | 6.26 | 331.01 | 147.97 | 24.86 |
|
Cash Conversion Cycle
|
89.33 | -- | 811.21 | -8.32 | 327.29 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
